Importantly, treatment with RO-3306, similar to treatment with apigenin, increased the expression of ID2 in HT1376 and HT1197 BC cells at both the transcript (Fig. 5e) and protein (Fig. 5f, g) levels. Here, ID2 is linked to breast cancer.